IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0321073.html
   My bibliography  Save this article

Exploring the impact of opioid use on outcomes in allogeneic hematopoietic stem cell transplantation

Author

Listed:
  • Tommy Alfaro Moya
  • Abel Santos Carreira
  • Shiyi Chen
  • Mats Remberger
  • Refik Saskin
  • Igor Novitzky-Basso
  • Jonas Mattsson

Abstract

Introduction: Hematological malignancies and allogeneic hematopoietic cell transplantation (alloHCT) often necessitate the use of opioids due to significant pain. This study aimed to investigate the impact of opioid use on the clinical outcomes of patients undergoing alloHCT. Methods: A retrospective cohort study was conducted by merging data from our local transplant database with anonymized pharmacy records obtained from the Institute for Clinical Evaluative Sciences (ICES). We analyzed 681 patients who underwent alloHCT at Princess Margaret Cancer Centre between January 2010 and December 2019. Patients who initiated opioid use within one-year post-alloHCT and had opioid prescriptions for more than 30 days were categorized as intense opioid users (IOU). Additionally, patients who started opioids before or within one-year post-alloHCT and had opioid prescriptions for less than 30 days but died while on opioids were also classified as IOU. The analytical code used for the analysis is available in the Supporting Information file. Results: Among the 681 patients, 51 were identified as IOU. The two-year overall survival (OS) was significantly lower in the IOU group, with 29.4% survival compared to 53% in non-IOU (HR 1.77, 95% CI 1.26–2.48, p = 0.0008). Multivariate analysis indicated that IOU status was associated with a 2.32 times higher instantaneous rate of death compared to non-IOU (HR 2.32, 95% CI 1.5–3.5, p = 0.002). The median time for relapse was 147 days in the IOU group (range 52–393) and 209 day for non-IOU (range 96–1793), p = 0.0082. Furthermore, the relapse rate at two years was notably higher in the IOU group (31.4% vs. 16.4%, p = 0.0049). The analysis of factors independently associated with relapse-free survival (LFS) showed that IOU status, age, donor type, and cytogenetic risk were significant predictors. At two years, relapse-free survival was 29.4% in the IOU group compared to 52.5% in the non-IOU group (p

Suggested Citation

  • Tommy Alfaro Moya & Abel Santos Carreira & Shiyi Chen & Mats Remberger & Refik Saskin & Igor Novitzky-Basso & Jonas Mattsson, 2025. "Exploring the impact of opioid use on outcomes in allogeneic hematopoietic stem cell transplantation," PLOS ONE, Public Library of Science, vol. 20(4), pages 1-13, April.
    • Handle: RePEc:plo:pone00:0321073
    DOI: 10.1371/journal.pone.0321073
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0321073
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0321073&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0321073?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0321073. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.